Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market

Executive Summary

India's Sun Pharma, the world's fifth largest specialty generic company, emphasized the "very competitive profile" of its late-stage psoriasis asset, tildrakizumab, at its Q2 earnings, but will that hold in a market that is expected to become increasingly saturated?

You may also be interested in...

Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials

Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales

Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options

Despite being able to show superiority over market leader AbbVie's Humira (adalimumab), Johnson & Johnson will need to invest heavily in order to drive uptake for guselkumab if the drug is successfully approved next year for the treatment of psoriasis.

Sun Builds On Tildrakizumab Hopes With Almirall Pact

Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts